-->

Company Registry

Aarden Pharmaceuticals Inc
Profile last edited on: 6/26/2019

Drugs targeting phosphatase family of proteins: emphasis on protein tyrosine phosphatases
Year Founded
2008
First SBIR Year
2013
Latest SBIR Award
2013
Program Status
Inactive

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

351 West 10th Street Suite 505
Indianapolis, IN 46202
   (317) 690-2453
   N/A
   www.aardenpharma.com
Multiple Locations:   
Congressional District:   07
County:   Marion

Public Profile

Aarden had been a small molecule drug discovery and development company. working with novel technology licensed from the labs of the Indiana University School of Medicine. The technology represented a chemistry breakthrough that could enable the firm to make drugs against a previously undruggable set of intracellular phosphatase (PTP) disease targets. Targeting the phosphatase family of proteins with emphasis on protein tyrosine phosphatases that catalyze the removal of phosphate groups from tyrosine residues of proteins and play key roles along with the tyrosine kinases in various signal transduction pathways, Arden Pharmaceuticals, Inc.'s drug program focus was on infectious diseases, cancer, metabolic, and autoimmune therapeutic areas. Record seems to suggest that firm ceased operation in/around 2013

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
1 NIH $249,269
Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (Mptpb) for Therapy Of

Key People / Management

  Gary M Noonan -- Chief Executive Officer; President

  Francis Burrows -- Chief Scientific Officer

  Thomas Estok -- Co-Founder & Director

  Christopher C LeMasters -- Co-Founder and Director

  Zhong-Yin Zhang -- Co-Founder and Director